Dr. Angela Shen, M.D., M.B.A has extensive experience in clinical development, medical affairs, and business development, having led clinical programs in oncology in a variety of pharmaceutical settings. Angela is currently the Chief Medical Officer for Arcellx, Inc. and NKarta Therapeutics, and is the Founder of Cell Therapy Accelerator LLC which has provided clinical and strategic support for a number of immuno-oncology programs, including cell and gene therapy.
Angela previously served as Chief Medical Officer of Battersea Biotech and Arvinas, Inc. Angela spent over six years with Novartis Oncology. As a Global Clinical Program Head, she helped launch the CART-19 (CTL019; Kymriah) Cell & Gene Therapy program and built a clinical and operations team from the ground up. As Head of Clinical Evaluation for the Novartis Oncology Business Development group, she was extensively involved in licensing in new compounds to strengthen the Novartis oncology and hematology pipeline, including CTL019 (Kymriah) and SelG1 (Crizanlizumab). Previously, Angela was a Clinical Lead at Novartis for the development of new oncology assets including panobinostat (Farydak) and inhibitors of the enzyme PI3-kinase. At Exelixis, Angela served as Clinical Lead for multiple drugs in early development, including cobimetinib (Cotellic), which was subsequently developed by Genentech and obtained FDA approval. At Johnson & Johnson, she held a medical affairs role supporting Velcade, Doxil, Yondelis, and Procrit. Early in her career, Angela was a research fellow at NIH, and research assistant in the lab of Dr. Paul Lauterbur (2003 Nobel Prize Laureate).
Angela received her MD from Albany Medical College in New York, followed by general surgery residency at Staten Island University Hospital, North Shore-LIJ Health System. She obtained her MBA, with a concentration in finance and management, from NYU Stern School of Business.